Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI

DOI: 10.1182/blood-2013-07-514448
Blood, 2013, 122, 3863-70.

#	Paper	IF	Citations
136	Busulfan or TBI: answer to an age-old question. *Blood*, **2013**, 122, 3856-7	2.2	8
135	Conditioning regimens in acute myeloid leukemia. **2014**, 7, 465-79		1
134	Transplantation in acute myeloid leukemia. **2014**, 28, 983-94		6
133	Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. *Blood*, **2014**, 124, 344-53	2.2	284
132	Hematopoietic stem cell transplantation-50 years of evolution and future perspectives. **2014**, 5, e0028		89
131	[Current indications of allogeneic stem cell transplant in adults with acute myeloid leukemia]. **2014**, 101, 856-65		1
130	Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. **2014**, 20, 415-20		13
129	Aldehyde dehydrogenases in acute myeloid leukemia. **2014**, 1310, 58-68		15
128	Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. **2014**, 20, 2034-41		26
127	Should busulfan now be part of the standard treatment for patients with acute myeloid leukemia?. **2014**, 3, 91-94		
126	Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?. **2014**, 9, 128-37		2
125	Complications of allogeneic hematopoietic stem cell transplantation. **2014**, 32, 349-62		50
124	Similar survival for patients undergoing reduced-intensity total body irradiation (TBI) versus myeloablative TBI as conditioning for allogeneic transplant in acute leukemia. **2014**, 89, 360-9		6
123	Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. **2014**, 6, 69-81		24
122	New approaches to transplantation in acute myelogenous leukemia. **2015**, 2015, 596-604		5
121	Late toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children. *Journal of Pediatric Hematology/Oncology*, **2015**, 37, e94-e101	1.2	5
120	Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. **2015**, 100, 269-74		22

119	Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy. **2015**, 8, 102		23
118	Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. *Blood*, **2015**, 126, 415-22	2.2	37
117	Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. **2015**, 21, 1299-307		118
116	Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. **2015**, 2, e384-92		33
115	Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics. **2015**, 8, 143-9		3
114	Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. **2015**, 21, 552-8		9
113	Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities. **2015**, 21, 412-20		9
112	A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. **2015**, 21, 1907-13		25
111	Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing. **2015**, 21, 1565-1575		12
110	Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. **2015**, 90, 144-8		22
109	Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. **2015**, 94, 1033-41		6
108	Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT. **2015**, 23, 3447-54		2
107	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. **2015**, 16, 1525-1536		103
106	Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation. **2015**, 21, 2141-2147		13
105	Conditioning regimens for refractory acute myeloid leukaemia. **2015**, 2, e354-5		
104	Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. **2015**, 21, 2129-2135		3
103	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective. *International Journal of Hematology*, **2015**, 101, 243-54	2.3	18
102	High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: time to rethink?. **2015**, 21, 620-4		30

101	Gli-1/PI3K/AKT/NF-kB pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells. **2016**, 7, 33004-15		45
100	Long-Term Outcomes after Treatment with Clofarabine □ Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. **2016**, 22, 1792-1800		9
99	Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients. **2016**, 15, 2802-11		17
98	Kinetics of versican-expressing macrophages in bone marrow after cord blood stem cell transplantation for treatment of acute myelogenous leukaemia. **2016**, 69, 906-11		5
97	Clinical Application of the Dried Blood Spot Method in the Measurement of Blood Busulfan Concentration. **2016**, 22, 1968-1973		14
96	Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity. **2016**, 1, 272-280		6
95	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. **2016**, 22, 1915-1925		82
94	Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. **2016**, 96, 90-7		15
93	Total Body Irradiation. **2016**, 341-357.e7		1
92	Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. **2016**, 22, 2194-2200		25
91	Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics. **2016**, 12, 1		12
90	Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma. **2016**, 11, 196-207		13
89	Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy. *Bone Marrow Transplantation*, **2016**, 51, 869-71	4.4	1
88	Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis. *Bone Marrow Transplantation*, **2016**, 51, 698-704	4.4	15
87	Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS. *Bone Marrow Transplantation*, **2016**, 51, 961-6	4.4	7
86	Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. *Bone Marrow Transplantation*, **2016**, 51, 351-7	4.4	37
85	Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. *Leukemia and Lymphoma*, **2016**, 57, 666-75	1.9	9
84	Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation. **2017**, 44, 529-538		5

83	Against the odds: haplo-cord grafts protect from GvHD and relapse. *Bone Marrow Transplantation*, **2017**, 52, 1590-1591	4.4	3
82	Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. **2017**, 123, 2671-2679		25
81	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*, **2017**, 129, 424-447	2.2	2764
80	Cytogenetics and outcome of allogeneic transplantation in first remission of acute myeloid leukemia: the French pediatric experience. *Bone Marrow Transplantation*, **2017**, 52, 516-521	4.4	8
79	Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. *Bone Marrow Transplantation*, **2017**, 52, 580-587	4.4	38
78	Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. **2017**, 23, 467-474		30
77	A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. **2017**, 23, 2088-2095		4
76	Hematopoietic Stem Cell Transplantation for Cancer. **2017**, 284-292		
75	A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplantation*, **2017**, 52, 59-65	4.4	12
74	Significance of an intensified myeloablative conditioning regimen for myeloid malignancy and acute lymphoblastic leukemia. **2017**, 7, 1-8		1
73	Hematopoietic Cell Transplants for Acute Myeloid Leukemia: Is There a Best Approach?. 316-327		
72	Hematopoietic Cell Transplants for Children with Acute Lymphoblastic Leukemia. 291-297		
71	Conditioning Regimens: Do They Really Matter?. 247-257		
70	Safety and Efficacy of Once-Daily Intravenous Busulfan in Allogeneic Transplantation: A Matched-Pair Analysis. **2018**, 24, 2139-2144		1
69	Effect of absolute monocyte count post-transplant on the outcome of patients with acute myeloid leukemia undergoing myeloablative allogeneic hematopoietic stem cell transplant with busulfan and cyclophosphamide conditioning. **2018**, 69, 60-65		0
68	Stem Cell Transplantation for Treatment of Malignancy. **2018**, 201-214		
67	A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. **2018**, 24, 1733-1740		11
66	Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission. **2018**, 18, 106-113		2

65	Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. *Leukemia and Lymphoma*, **2018**, 59, 837-843	1.9	7
64	. **2018**,		
63	An investigation on the predominant diseases, its diagnosis, and commonly used drugs in the poultry farms in the North-Eastern regions of Algeria. **2018**, 11, 986-989		3
62	Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. **2018**, 67, 49-59.e1		4
61	TBI: To Be (Irradiated) or Not To Be? That Remains the Question. **2018**, 24, 1535-1536		1
60	Total Body Irradiation-Based versus Chemotherapy-Based Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplant. **2019**, 25, e356-e362		3
59	The Role of Radiation Therapy in Hematopoietic Stem Cell Transplantation. **2019**, 59-72		0
58	132. Risk factors for cage migration and cage retropulsion following transforaminal lumbar interbody fusion. **2019**, 19, S64		
57	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. **2019**, 25, 2398-2407		8
56	Comparison of Different Conditioning Regimens in Allogeneic Hematopoietic Stem-Cell Transplantation Shows Superiority of Total Body Irradiation-Based Regimen for Younger Patients With Acute Leukemia: A Nationwide Study. **2019**, 19, e605-e615		4
55	Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. *Bone Marrow Transplantation*, **2019**, 54, 2013-2019	4.4	6
54	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. **2019**, 25, 1424-1431		9
53	Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation. *Bone Marrow Transplantation*, **2019**, 54, 1614-1624	4.4	6
52	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. **2019**, 139-158		0
51	Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. *Leukemia and Lymphoma*, **2019**, 60, 639-648	1.9	8
50	Bayesian non-parametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation. **2019**, 68, 809-828		4
49	Allogeneic hematopoietic cell transplantation; the current renaissance. **2019**, 34, 34-44		28
48	Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. **2019**, 285, 407-418		21

47	Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicity. *Leukemia and Lymphoma*, **2019**, 60, 726-733	1.9	1
46	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. **2020**, 26, 292-299		5
45	Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. **2020**, 26, 323-332		9
44	Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy. *International Journal of Hematology*, **2020**, 111, 247-255	2.3	1
43	Comparison of total body irradiation non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. **2021**, 106, 1839-1845		7
42	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. **2020**, 4, 983-992		21
41	Towards homogenization of total body irradiation practices in pediatric patients across SIOPE affiliated centers. A survey by the SIOPE radiation oncology working group. **2021**, 155, 113-119		9
40	Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission. *Bone Marrow Transplantation*, **2021**, 56, 232-242	4.4	
39	Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning. **2021**, 20, 684-694		1
38	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplantation*, **2021**, 56, 491-491	4.4	0
37	Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis. **2021**, 26, 186-198		0
36	Current Use of Total Body Irradiation in Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation. *Journal of Korean Medical Science*, **2021**, 36, e55	4.7	1
35	Transplant Pharmacology and Conditioning Therapy. *Organ and Tissue Transplantation*, **2021**, 315-346	0	
34	Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?. *Current Oncology*, **2021**, 28, 903-917	2.8	4
33	Feasibility of an intensified myeloablative conditioning regimen consisting of busulfan, fludarabine, cytarabine, and total body irradiation before single cord blood transplantation in elderly patients. *International Journal of Hematology*, **2021**, 114, 85-93	2.3	3
32	Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adult Patients with Acute Myeloid Leukemia. *Transplantation and Cellular Therapy*, **2021**, 27, 314.e1-314.e10		1
31	Successful Bone Marrow Transplantation With Intensive Post-transplant Intrathecal Chemotherapy for CNS Relapsed AML in 2 Infants. *Journal of Pediatric Hematology/Oncology*, **2021**,	1.2	0
30	Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay. *Transplantation and Cellular Therapy*, **2021**, 27, 431.e1-431.e8		1

29	Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. *Pediatric Blood and Cancer*, **2021**, 68, e29087	3	1
28	Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT. *Cancer Medicine*, **2021**, 10, 4250-4268	4.8	1
27	Impact of a Bayesian Individualization of Cyclosporine Dosage Regimen for Children Undergoing Allogeneic Hematopoietic Cell Transplantation: A Cost-Effectiveness Analysis. *Therapeutic Drug Monitoring*, **2021**, 43, 481-489	3.2	0
26	Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis. *Bone Marrow Transplantation*, **2021**, 56, 3008-3015	4.4	0
25	Lung Injury Induced by Antitumor Drugs: Prevalence, Certain Drugs and Their Mechanisms of Action. Part 2. *Tuberculosis and Lung Diseases*, **2021**, 99, 54-60	0.6	
24	Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). *Journal of Cancer Research and Clinical Oncology*, **2021**, 1	4.9	1
23	Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing Program. *Therapeutic Drug Monitoring*, **2021**, 43, 657-663	3.2	0
22	Acute Myeloid Leukemia in Children. **2019**, 523-530		2
21	The GTT CYP2B6 germline polymorphism affects the risk of acute myeloid leukemia and is associated with specific chromosomal abnormalities. *PLoS ONE*, **2014**, 9, e88879	3.7	10
20	Conditioning regimen of single-unit cord blood transplantation for hematological malignancy. *Journal of Illusion*, **2021**, 10, 145-152		
19	Acute Myeloid Leukemia. **2017**, 61-85		
18	A Single-Center Experience With Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia: A Modest Pitch for Non-Total Body Irradiation Conditioning Regimens. *Experimental and Clinical Transplantation*, **2019**, 17, 243-250	0.8	
17	Transplant Pharmacology and Conditioning Therapy. *Organ and Tissue Transplantation*, **2020**, 1-32	0	
16	The Role of Stem Cell Transplant in the Therapy of Acute Myeloid Leukemia (AML). *Hematologic Malignancies*, **2021**, 111-131	0	
15	[Effect of cyclophosphamide on hematopoietic stem cells in mice with iron overload]. *Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University*, **2020**, 40, 110-117	0.5	
14	[How I treat adult malignant hematological diseases with single cord blood transplantation]. *Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi*, **2019**, 40, 449-452	0.4	0
13	[The family and clinical analysis of matched parent-child in hematopoietic stem cell transplantation]. *Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi*, **2018**, 39, 425-430	0.4	
12	Total Body Irradiation in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions.. *Frontiers in Pediatrics*, **2021**, 9, 774348	3.4	2

11	Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse.. *Frontiers in Oncology*, **2022**, 12, 802648	5.3	0
10	Myeloablative versus reduced-intensity conditioning with fludarabine/busulfan for myelodysplastic syndrome: A propensity score-matched analysis.. *Transplantation and Cellular Therapy*, **2022**,		0
9	Two Different Transplant Preconditioning Regimens Combined with Irradiation and Chemotherapy in the Treatment of Childhood Leukemia: Systematic Review and Meta-Analysis.. *Journal of Healthcare Engineering*, **2022**, 2022, 2825712	3.7	
8	Total body irradiation-based versus busulfan-based myeloablative conditioning for single-unit cord blood transplantation in adults.. *Leukemia and Lymphoma*, **2021**, 1-11	1.9	
7	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan □ clofarabine in allogeneic stem cell transplantation. *Bone Marrow Transplantation* ,	4.4	
6	Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis.		0
5	Individualized busulfan dosing improves outcomes compared to fixed dose administration in pre-transplant MRD positive AML patients with intermediate risk undergoing allogeneic stem cell transplantation in CR.		0
4	Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies. 12,		0
3	Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy.		0
2	ACR□ARS Practice Parameter for the Performance of Total Body Irradiation. Publish Ahead of Print,		0
1	Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy.		0